Original Source(s)
Related Content
Naive-Like T Cells Linked to CAR T Durability
Higher proportions of less-differentiated T cells were associated with longer progression-free survival in a 783-patient lymphoma analysis
November 4, 2026
-
3 min
ESMO26: Toni Choueiri, MD, on KEYNOTE-564
Final analysis of the pivotal KEYNOTE-564 trial in kidney cancer presented by Toni Choueiri, MD. After 7 years of follow-up, adjuvant pembrolizumab continued to extend disease-free survival and overall survival in high-risk clear-cell renal cell carcinoma.
November 17, 2026
-
1 min